Targeted Therapy for Lung Cancer: — Which Mutation You Have and What It Means

Small cell lung cancer is treated very differently from non-small cell lung cancer. The targeted drugs used in NSCLC — EGFR inhibitors, ALK inhibitors, and the rest — are not part of standard SCLC treatment. SCLC is primarily treated with chemotherapy and, in some patients, immunotherapy. Research into targetable mutations in SCLC is ongoing, but none have changed routine clinical practice in the way that driver mutation-matched therapy has in NSCLC. If you have SCLC, ask your oncologist directly what systemic therapies are being considered and on what basis.

Comprehensive next-generation sequencing results usually take one to three weeks from the date the laboratory receives the sample. Targeted single-gene tests — for EGFR alone, for example — can return faster. If the original biopsy tissue is insufficient, a repeat biopsy or a liquid biopsy from blood may be needed before testing can begin, which adds time. Ask your team when the sample was sent and when results are expected so you have a clear timeline rather than open-ended waiting.

Most targeted therapies eventually stop controlling the tumour through a process called acquired resistance. When this happens, re-testing — through a new biopsy or a liquid biopsy — is often the next step, because the mechanism of resistance can identify the drug most likely to work next. In EGFR-positive lung cancer, specific resistance mutations are well characterised and predict which treatment is likely to be effective. Progression on targeted therapy is not the end of options; for many patients it is the beginning of a new treatment phase.

In most cases, no — and this is not a gap in care. For EGFR- and ALK-positive lung cancer, combining immunotherapy with targeted therapy has been studied and found to increase side effects without improving outcomes, which is why current NCCN and ESMO guidelines do not recommend the combination. The two are usually sequenced rather than combined. There are specific settings where combinations are studied and used, but these are defined by clinical trial evidence. Your oncologist's recommendation will be based on your mutation and treatment line.

Yes. Targeted therapy is given as day care at CION centres, so most patients do not need an overnight hospital stay. Response-assessment imaging, including PET-CT, is coordinated with partner imaging centres. Molecular testing — the comprehensive panel your oncologist orders to establish eligibility — is arranged at the time of your diagnostic workup. CION does not provide CAR-T or cell therapy; if that is being considered separately, you would be referred to a centre that offers it.

EGFR mutations are classified as common or uncommon because they can respond differently to the same drugs. The two most common types are exon 19 deletions and the exon 21 L858R substitution — these respond well to currently approved EGFR inhibitors and are treated similarly in most guidelines. Uncommon EGFR mutations are a more varied group: some respond to standard inhibitors, and some do not, which is why the approach may differ. Ask your oncologist to name your specific mutation type — the exon number and the exact change — and to explain how it influences which drug is recommended.